# US 2010/0166872 A1 · Novel improved compositions for cancer therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166872 A1
- Document ID: US20100166872A1
- Status: Published application
- Kind: A1
- Application number: 12/083,594
- Filed: 2006-10-19
- Published: 2010-07-01
- Earliest claimed: 2005-10-21
- Inventors: Amarjit Singh; Singh Sarabjit; Ajay K. Gupta; Mangesh M. Kulkarni
- Web page: https://patentgrep.com/patent/US20100166872A1

## CPC

- A61K 9/5138: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/5169: {Proteins, e.g. albumin, gelatin}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel and improved compositions of anticancer drugs, preferably taxanes, such as paclitaxel and docetaxel, their derivatives or their analogues, methods of manufacturing these compositions and methods of fractionating the particles in particular size range and methods of treating cancer patients with these compositions, which provide reduced chemotherapy-induced side-effects especially reduced chemotherapy-induced-alopecia. The composition is such that there is substantially no free drug in the said composition.

## Claims

### Claim 1

Novel and improved compositions for cancer therapy having substantially reduced chemotherapy-induced side-effects like alopecia.

### Claim 2 (depends on 1)

Novel and improved compositions for cancer therapy according to claim 1 comprising particles of at least one anticancer drug and at least one polymer.

### Claim 3 (depends on 2)

Novel and improved compositions for cancer therapy according to claim 2 wherein the particles are present within a defined particle size range; the composition being such that it produces substantially reduced chemotherapy-induced side-effects like alopecia.

### Claim 4 (depends on 2)

Novel and improved compositions for cancer therapy according to claim 2 wherein the particles have D10≧80 nm, D50 of about 200 nm and D90≦450 nm.

### Claim 5 (depends on 2)

Novel and improved compositions for cancer therapy according to claim 2 wherein the particles have D10≧120 nm, D50 of about 200 nm and D90≦350 nm.

### Claim 6 (depends on 2)

Novel and improved compositions for cancer therapy according to claim 2 wherein the particles have D10≧140 nm, D50 of about 200 nm and D90≦260 nm.

### Claim 7 (depends on 2)

Novel and improved compositions for cancer therapy according to claim 2 wherein said composition has substantially no free drug and wherein said drug is substantially completely associated with the polymer(s)

### Claim 8 (depends on 2)

Novel and improved compositions for cancer therapy according to claim 2 wherein said particles have a particle size distribution ratio of D90/D10 less than 4.0.

### Claim 9 (depends on 2)

Novel and improved compositions for cancer therapy according to claim 2 wherein said particles have a particle size distribution ratio of D90/D10 less than 3.0.

### Claim 10 (depends on 2)

Novel and improved compositions for cancer therapy according to claim 2 wherein said particles have a particle size distribution ratio of D90/D10 less than 2.0.

### Claim 11 (depends on 2)

Novel and improved compositions for cancer therapy according to claim 2 wherein the anticancer drug is selected from the group consisting of alkylating agents, antimetabolites, antibiotic anticancer agents, plant alkaloids, anthracenediones, natural products, hormones, hormones antagonists, miscellaneous agents, radiosensitizers, platinum coordination complexes, adrenocortical suppressants, immunosuppressive agent, functional therapeutic agents, gene therapeutic agent, antisense therapeutic agent, tyrosine kinase inhibitor, monoclonal antibody, immunotoxin, radioimmunoconjugate, cancer vaccine, interferon, interleukin, substituted ureas, taxanes and COX-2 inhibitors.

### Claim 12 (depends on 11)

Novel and improved compositions for cancer therapy according to claim 11 wherein the anticancer drug is one or more of chlormethine, chlorambucile, busulfan, thiotepa, chlorambucil, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, melphalan, uramustine, carmustine, lomustine, streptozocin, dacarbazine, procarbazine, temozolamide, cisplatin, carboplatin, oxaliplatin, satraplatin, (SP-4-3)-(cis)-amminedichloro-[2-methylpyridine}-platinum(II), methotrexate, permetrexed, raltitrexed, trimetrexate, cladribine, chlorodeoxyadenosine, clofarabine, fludarabine, mercaptopurine, pentostatin, thioguanine, azacitidine, capecitabine, cytarabine, edatrexate, floxuridine, 5-fluorouracil, genicitabine, troxacitabine, bleomycin, dactinomycin, adriamycin, actinomycin, mithramycin, mitomycin, mitoxantrone, porfiromycin, daunorubicin, doxorubicin, liposomal doxorubicin, epirubicin, idarubicin, vairubicin, phenesterine, tamoxifen, piposulfancamptothesin, L-asparaginase, PEG-L-asparaginase, paclitaxel, docetaxel, taxotere, vinblastine, vincristine, vindesine, vinorelbine, irinotecan, topotecan, amsacrine, etoposide, teniposide, fluoxymesterone, testolactone, bicalutamide, cyproterone, flutamide, nilutamide, aminoglutethimide, anastrozole, exemestane, formestane, letrozole, dexamethasone, prednisone, diethylstilbestrol, fulvestrant, raloxifene, tamoxifen, toremifine, buserelin, goserelin, leuprolide, triptorelin, medroxyprogesterone acetate, megestrol acetate, levothyroxine, liothyronine, altretamine, arsenic trioxide, gallium nitrate, hydroxyurea, levamisole, mitotane, octreotide, procarbazine, suramin, thalidomide, methoxsalen, sodium porfimer, bortezomib, erlotinib hydrochloride, gefitinib, imatinib mesylate, semaxanib, adapalene, bexarotene, trans-retinoic acid, 9-cis-retinoic acid, and N-(4-hydroxyphenyl)retinamide, alemtuzumab, bevacizumab, cetuximab, ibritumomab tiuxetan, rituximab, trastuzumab, gemtuzumab ozogamicin, tositumomab, interferon-α2a, interferon-α2b, aldesleukin, denileukin diftitox, and oprelvekin and derivatives thereof and the like.

### Claim 13 (depends on 12)

Novel and improved compositions for cancer therapy according to claim 12 wherein the anticancer drug is selected from taxanes, doxorubicin, and 5-fluorouracil.

### Claim 14 (depends on 13)

Novel and improved compositions for cancer therapy according to claim 13 wherein the anticancer drug is taxanes and derivatives thereof.

### Claim 15 (depends on 14)

Novel and improved compositions for cancer therapy according to claim 14 wherein the taxane is chosen from paclitaxel and docetaxel.

### Claim 16 (depends on 2)

Novel and improved compositions for cancer therapy according to claim 2 wherein the polymer is biodegradable polymer.

### Claim 17 (depends on 16)

Novel and improved compositions for cancer therapy according to claim 16 wherein the biodegradable polymer is selected from a group comprising proteins, peptides, fatty acids, lipids, phospholipids, polynucleic acid, polysaccharides, proteoglycans, lipoproteins, ∝-hydroxycarboxylic acids, poly(ε-caprolactone), poly(β-hydroxybutyrate), poly(hydroxyvalerate) and (β-hydroxybutyrate-hydroxyvalerate) copolymers, polymalic acid, poly(lactic acid), poly(glycolic acid), poly(d,l-lactic-co-glycolic acid), amphiphilic block polymers of polylactic acid-polyethylene oxide, polyalkylene glycol, polyethylene oxides, block copolymers of polyethylene oxide-polypropylene oxide, polyanhydrides, polyorthoesters, polyphosphazanes, pullulan, poly(N-vinyl pyrrolidone), polyvinyl alcohol, polyvinyl acetate, polyesters, polyaminoacids, polyacrylates, polyvinyl pyrrolidone, polyethoxyzoline and other synthetic and natural polymers or co-polymers thereof and the like and derivatives and mixtures thereof.

### Claim 18 (depends on 17)

Novel and improved compositions for cancer therapy according to claim 17 wherein said protein is albumin.

### Claim 19 (depends on 2)

Novel and improved compositions for cancer therapy according to claim 2 wherein said composition comprise from about 0.5% to about 99.5% by weight of said anticancer drug and from about 2.0% to about 99.0% by weight of said polymer(s).

### Claim 20 (depends on 2)

Novel and improved compositions for cancer therapy according to claim 2 wherein the anticancer drug is paclitaxel and polymer is poly(d,l-lactic-co-glycolic acid).

### Claim 21 (depends on 2)

Novel and improved compositions for cancer therapy according to claim 2 wherein the anticancer drug is paclitaxel and polymer is albumin.

### Claim 22 (depends on 2)

Novel and improved compositions for cancer therapy according to claim 2 further comprising a secondary polymer.

### Claim 23 (depends on 22)

Novel and improved compositions for cancer therapy according to claim 22 wherein the secondary polymer is selected from the group consisting of temperature and pH sensitive polymers.

### Claim 24 (depends on 23)

Novel and improved compositions for cancer therapy according to claim 23 wherein the temperature and/or pH sensitive polymers is selected from the group consisting of poly(N-acetylacrylamide), poly(N-isopropylacrylamide), poly(N-isopropylacrylamide-co-acrylamide), polyvinylalcohol, polyethyleneglycol, polyacrylamide, poly(methacrylamide) and the like and derivatives thereof.

### Claim 25 (depends on 24)

Novel and improved compositions for cancer therapy according to claim 24 wherein said temperature and/or pH sensitive polymer is poly(N-isopropylacrylamide).

### Claim 26 (depends on 19)

Novel and improved compositions for cancer therapy according to claim 19 further comprising secondary polymer in an amount from about 0.5% to about 99.0%, from about 1.0% to about 95.0% and from about 2.0% to about 90.0% by weight of the said composition.

### Claim 27 (depends on 22)

Novel and improved compositions for cancer therapy according to claim 22 wherein in presence of the secondary polymer, particles of the composition, upon administration to a mammal, increases in size to about two times its original size in plasma and to about ten times its original size at the tumor site, thus providing targeting and substantially reduced chemotherapy-induced side-effects like alopecia.

### Claim 28 (depends on 2)

Novel and improved compositions for cancer therapy according to claim 2 wherein said composition is a colloidal delivery system.

### Claim 29 (depends on 28)

Novel and improved compositions for cancer therapy according to claim 28 wherein the colloidal delivery system is lyophillized.

### Claim 30 (depends on 28)

Novel and improved compositions for cancer therapy according to claim 28 wherein the colloidal delivery system is such that the particles are suspended in a biocompatible aqueous liquid.

### Claim 31 (depends on 1)

Novel and improved compositions for cancer therapy according to claim 1 wherein the composition comprises paclitaxel in an amount from about 0.5% to about 99.5%, poly(d,l-lactic-co-glycolic acid) in an amount from about 2.0% to about 99.0% and optionally poly(N-isopropylacrylamide) in an amount from about 2.0% to about 90.0%, and one or more pharmaceutically acceptable excipients, carriers or a combination thereof from about 0.01% to about 99.9% by weight of the composition.

### Claim 32 (depends on 1)

Novel and improved compositions for cancer therapy according to claim 1 wherein the composition comprises paclitaxel in an amount from about 0.5% to about 99.5%, albumin in an amount from about 2.0% to about 99.0% and optionally poly(N-isopropylacrylamide) in an amount from about 2.0% to about 90.0%, and one or more pharmaceutically acceptable excipients, carriers or a combination thereof from about 0.01% to about 99.9% by weight of the composition.

### Claim 33 (depends on 1)

A method of making a novel and improved composition for cancer therapy according to claim 1 comprising the steps of (i) mixing at least one anticancer drug with at least one polymer in a solvent (ii) optionally carrying out step (i) in the presence of one or more pharmaceutically acceptable carriers (iii) obtaining nanoparticles by removing the solvent and (iii) subjecting the nanoparticles to particle sizing such that the obtained particles have D10≧80 nm, D50 of about 200 nm and D90≦450 nm and have substantially no free drug; the composition being such that it provides substantially reduced chemotherapy-induced side-effects like alopecia.

### Claim 34

A method of treating a mammal for cancer therapy comprising the step of administering to the mammal a therapeutically effective amount of the said novel and improved compositions comprising particles of at least one anticancer drug and at least one polymer wherein the particles have D10≧80 nm, D50 of about 200 nm and D90≦450 nm and the composition being such that it has substantially no free drug and provides a substantially reduced chemotherapy-induced side-effects like alopecia.

### Claim 35

A method for reducing chemotherapy-induced side-effects like alopecia of a cancer therapy in a mammal undergoing treatment with anticancer drugs, said method comprising administering a therapeutically effective amount of the said novel and improved compositions comprising particles of at least one anticancer drug and at least one polymer wherein the particles have D10≧80 nm, D50 of about 200 nm and D90≦450 nm and the composition being such that it has substantially no free drug.
